This formula is particularly well suited to:

Adult female hormonal acne: The defining indication. Women with acne that flares premenstrually, that localizes to the lower face, jaw, and chin, that emerged or worsened in the 30s or 40s, or that has been resistant to antibiotic-based topical and oral therapy — all patterns strongly suggesting androgenic sebaceous drive — are the ideal candidates for this formula's spironolactone component.

Inflammatory acne (papulopustular): Active inflammatory papules and pustules respond to the dual antibacterial activity and multi-point anti-inflammatory coverage of clindamycin and azelaic acid.

Comedonal acne: Non-inflammatory comedones (blackheads, whiteheads) and the microcomedone precursor lesions respond to azelaic acid's keratolytic and comedolytic activity.

Mixed comedonal and inflammatory acne: The most common presentation — simultaneous comedonal and inflammatory lesions of varying severity — is addressed comprehensively by this formula's combined keratolytic, antibacterial, and anti-inflammatory mechanisms.

Acne with significant post-inflammatory

hyperpigmentation: Patients — particularly those with Fitzpatrick skin types III–VI — for whom PIH is as significant a concern as active acne benefit from azelaic acid's concurrent tyrosinase inhibition, addressing PIH in the same application that treats active lesions.

Perimenopausal acne: Women experiencing the hormonal shift of perimenopause — characterized by declining estrogen and a relative androgenic environment — frequently develop new-onset or significantly worsened acne that responds poorly to conventional treatments. Topical spironolactone's local anti-androgenic activity addresses the hormonal driver of this presentation directly.

With consistent use as directed by your prescribing provider:

Reduction in active inflammatory acne lesions — papules, pustules, and nodules — through dual antibacterial and multi-point anti-inflammatory activity

Clearance of comedonal acne through azelaic acid's keratolytic normalization of follicular hyperkeratinization

Reduced sebum production through topical anti-androgenic activity, depleting the environment that sustains bacterial proliferation and comedone formation

Prevention of new lesion formation through hormonal sebaceous modulation, microcomedone prevention, and sustained bacterial suppression

Reduction in post-inflammatory hyperpigmentation through tyrosinase inhibition — clearing the dark spots that outlast resolved acne lesions

Resistance-conscious bacterial management through dual-mechanism antibacterial coverage that reduces selective pressure for C. acnes antibiotic resistance

Anti-inflammatory coverage at multiple cascade points — from neutrophil chemotaxis to ROS scavenging to leukotriene inhibition

Improvement in overall skin texture, evenness, and tone as active acne, comedones, and PIH resolve together

Sustained improvement in hormonal acne that has been resistant to antibiotic-only or keratolytic-only topical therapy

Results vary by individual. Some improvement in inflammatory lesion count is often noticeable within four to six weeks. Meaningful reduction in comedonal acne, PIH, and hormonally driven breakouts typically develops over eight to twelve weeks of consistent use. Hormonal acne management generally requires ongoing therapy; results diminish if treatment is discontinued without addressing the underlying androgenic drive.

Apply as directed by your prescribing provider. Dosing frequency and application area will be individualized to your acne presentation and treatment response. General guidance is provided below.

Application Instructions:

Cleanse the face with a gentle, non-comedogenic cleanser and pat dry.

Dispense a small amount and apply a thin, even layer to the affected areas. A pea-sized amount is typically sufficient for the full face; use less for localized application to specific affected zones.

Apply gently — avoid rubbing vigorously, which can exacerbate inflammation and irritate active lesions.

Avoid the eyes, inner corners of the nose, and mucous membranes.

Wash hands after application.

Allow to absorb before applying moisturizer, sunscreen, or makeup.

Sun Protection: Daily broad-spectrum SPF 30 or higher is strongly recommended. Acne-prone skin is often sensitized, and UV exposure worsens post-inflammatory pigmentation — the hyperpigmentation that persists at resolved lesion sites. Non-comedogenic, oil-free formulations are preferred to avoid occlusion of follicular ostia.

Starting Protocol: Some patients — particularly those with sensitive or reactive skin — may experience mild initial tingling, warmth, or dryness during the first one to two weeks as the formula establishes consistent activity. This is typically transient. Begin with once-daily application if twice-daily is prescribed and your skin is reactive; advance to the full prescribed frequency as tolerated.

This is a prescription-only compounded medication. Full patient counseling is required before initiating therapy.

Contraindications:

Pregnancy: Spironolactone has documented fetal risk — it has shown feminization of male rat fetuses in animal studies, and is generally avoided in pregnancy as a precaution. Women of reproductive age using this formula should use reliable contraception and discontinue immediately if pregnancy is confirmed or planned. Azelaic acid is among the few acne actives considered relatively safe in pregnancy at typical concentrations — however, the spironolactone component makes this formula contraindicated during pregnancy overall. Consult your provider immediately if pregnancy occurs.

Breastfeeding: Safety of topical spironolactone and clindamycin during lactation has not been fully established. Consult your provider before use.

Known hypersensitivity: Patients with documented allergy to spironolactone, clindamycin or lincomycin, or azelaic acid should not use this product.

History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis: Systemic clindamycin is associated with Clostridioides difficile colitis; topical clindamycin carries a very low but documented risk of systemic absorption and GI effects in patients with pre-existing inflammatory bowel conditions. Discuss this history with your prescribing provider before initiating therapy.

Potential Side Effects:

Common:

Mild tingling, stinging, or warmth at application — particularly with azelaic acid, most common during the first one to two weeks; typically resolves with continued use

Mild dryness or peeling, particularly during initial adjustment

Mild erythema at application site

Less common:

Contact dermatitis in patients with sensitivity to any formula component

Rare local skin depigmentation at application site with azelaic acid — more common at higher concentrations; report to your provider if it occurs

Rare GI symptoms from systemic clindamycin absorption — report promptly, particularly if diarrhea is severe or prolonged (see colitis note above)

Rare local skin irritation from spironolactone component in sensitive skin patients

Important note for patients with darker skin tones: Azelaic acid's tyrosinase inhibition can occasionally produce localized hypopigmentation (lightening beyond PIH correction) at application sites in very high skin phototypes. Monitor for unintended lightening and discuss with your provider.

Seek provider evaluation if: irritation is severe or worsening beyond two to three weeks, spreading rash or blistering develops, significant GI symptoms occur, or pregnancy is confirmed or planned.

Other topical antibiotics: Concurrent use of additional topical antibiotic preparations increases resistance selection pressure and irritation risk without established additive benefit. Avoid combining topical antibiotics without provider direction.

Topical retinoids (tretinoin, adapalene, tazarotene): Retinoids and azelaic acid both drive keratinocyte turnover — concurrent use can significantly increase irritation and barrier disruption. Some providers use these combinations intentionally in supervised protocols; do not combine without explicit provider direction.

Topical exfoliating acids: AHAs and BHAs applied concurrently increase barrier disruption risk and may amplify azelaic acid's keratolytic activity beyond the intended therapeutic level.

Oral spironolactone: Patients on systemic spironolactone for any indication (hypertension, heart failure, oral hormonal acne management) should inform their provider — combined systemic and topical exposure should be considered in the overall treatment plan, though meaningful systemic additive effect from topical facial spironolactone is unlikely at typical compounded concentrations.

Potassium-sparing agents and ACE inhibitors: Clinically relevant primarily with oral spironolactone at systemic doses; topical facial application produces minimal systemic absorption but patients on these medications should inform all prescribing providers.

Benzoyl peroxide: Does not chemically interact with these actives the way it inactivates tretinoin, but concurrent use with clindamycin is actually a clinically common strategy to reduce C. acnes resistance selection. If your provider has prescribed benzoyl peroxide as part of a combination protocol, follow their specific timing and sequencing guidance.

NSAIDs: Topically applied; no clinically significant interaction anticipated at typical compounded facial concentrations.

Store at room temperature, 68°F – 77°F (20°C – 25°C), away from direct heat, humidity, and light

Keep container tightly closed

Do not freeze

Keep out of reach of children

Do not use beyond the labeled expiration date

If refrigeration is specified on your label, store accordingly